Epithelioid Sarcoma Market is segmented By Therapy (Surgery, Radiation Therapy, Chemotherapy), By Type (Localized Sarcoma, Metastatic Sarcoma), By Drug Type (TK Inhibitors, mTOR Inhibitors), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa). The report offers the value (in USD Billion) for the above-mentioned segments.
Market Size in USD
CAGR9.1%
Study Period | 2024 - 2031 |
Base Year of Estimation | 2023 |
CAGR | 9.1% |
Market Concentration | High |
Major Players | Epizyme, Eli Lilly and Company, Pfizer, Merck Sharp & Dohme, GlaxoSmithKline |
The epithelioid sarcoma market is estimated to be valued at USD 1.44 Bn in 2024 and is expected to reach USD 2.88 Bn by 2031, growing at a compound annual growth rate (CAGR) of 9.1% from 2024 to 2031. The market for epithelioid sarcoma has been growing in high single digits owing to the rising incidence of soft tissue cancers as well as increasing access to healthcare in developing regions.